OpenAI’s Startup Fund and Peter Thiel’s Founders Fund joined a $45 million seed round for Coherence, a company developing a button-sized brain implant intended to detect and electrically intervene against cancer activity. Coherence’s SOMA implant pairs with an over-ear removable wearable and an app to deliver continuous monitoring data. The company said it has initiated safety testing with 30-minute implant placements during other surgeries, with plans to move toward a first chronic human trial in glioblastoma and to pursue FDA breakthrough device designation. It also positioned the platform for expansion into additional oncology settings, including pancreatic cancer. For investors and device-focused biopharma teams, the event highlights how AI-backed capital is flowing into closed-loop, neuro-oncology technologies—while the near-term regulatory gate will likely center on safety, signal validity, and the evidentiary bar for device-directed tumor control.